Exclusive Global License Agreement with Zoetis
- Anatara has signed an exclusive agreement with Zoetis Inc., the leading global animal health company, to license Detach(R) - Anatara's non-antibiotic approach to aid in the control of diarrhoeal disease in livestock and horses
- Zoetis to manage worldwide development, manufacturing, distribution and marketing of Detach(R) for livestock animals and horses
- Agreement represents the achievement of a major milestone for Anatara and its shareholders
Under the terms of the license agreement, Anatara has granted Zoetis exclusive rights to develop, manufacture, distribute and market Detach(R) worldwide, including in Australia. The agreement follows an initial Exclusive Research Evaluation and License Option period (announced 18th January 2016), during which time Zoetis evaluated Detach(R) for use as a non-antibiotic product in livestock species.
The terms of the agreement include an upfront payment, milestone payments and royalties based on product sales. Intellectual property exclusively licensed to Zoetis under the agreement shall remain the sole property of Anatara. Exact details of the agreement remain confidential.
Anatara's Executive Chairman, Dr Mel Bridges said, "Through signing this agreement with Zoetis, Anatara has reached a major commercial milestone - this an exciting moment for our shareholders."
Dr Bridges added, "The global reach and resources that Zoetis is able to apply to making Detach(R) a successful product is of great value to Anatara. We see this as an outstanding result with a world-leading partner."
"Veterinarians and livestock farmers are seeking new, integrated solutions to help keep animals healthy," said Dr. Scott A. Brown, Vice President, External Innovation at Zoetis. "We look forward to continuing our research and development of this novel approach and intend to explore its place in our diverse portfolio of solutions to prevent and treat gastrointestinal illness in livestock animals and horses."
Anatara's Detach(R) technology has the potential to play an important role as an alternative to traditional antibiotics to control gastrointestinal diseases in livestock and production animals. The agreement demonstrates both companies' commitment to the responsible use of antibiotics in the food chain and finding natural alternatives to help control gastrointestinal disease.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Anatara Lifesciences Ltd